Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3760 - MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role


09 Oct 2016


Poster display


Ardi Pambuku


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


A. Pambuku1, G. Lombardi1, R. Bertorelle2, L. Bellu1, P. Fiduccia2, M. Gardiman3, A. Della Puppa4, F. Berti5, D. D'Avella6, V. Zagonel1

Author affiliations

  • 1 Department Of Clinical And Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, 35100 - Padova/IT
  • 2 Department Of Clinical And Experimental Oncology, Clinical Trials And Biostatistics Unit And Molecular Immunology And Oncology Unit, Istituto Oncologico Veneto IRCCS, Padova/IT
  • 3 Deaprtment Of Pathology, Azienda Ospedaliera Padova, 35100 - Padova/IT
  • 4 Neurosurgery Department, Azienda Ospedaliera Padova, 35100 - Padova/IT
  • 5 Radiotherapy, Veneto Institute of Oncology, 35100 - Padova/IT
  • 6 Neurosurgery Department, University of Padova, 35100 - Padova/IT


Abstract 3760


MGMT gene promoter methylation status is acknowledged as a prognostic factor and predictive marker for temozolomide (TMZ) treatment. Although MGMT status determined by pyrosequencing was showed to correlate with progression free survival (PFS) and overall survival (OS), it is still unclear a cut-off value that discriminates between methylated and unmethylated patient (pts) and its correlation with the patient clinical outcome.


We analyzed the tissue samples from 128 PTS diagnosed with GBM from November 2009 to December 2015. All PTS underwent treatment with RT + TMZ and had an ECOG-PS 0-2. Methylation percentage for each sample was obtained by calculating the average methylation of all 10CpG sites (75-84) of MGMT promoter by pyrosequencing analysis. PTS with 0-6% of methylation were classified as unmethylated (UM), PTS with 7-24% as low methylated (LM) and PTS with ≥ 25% as high methylated (HM). 25% was the median value of methylation of our PTS having >6% of methylation.


Median age was 60 yrs (range 25-84), 60.9% were male, 74.2% had an ECOG PS 0-1, 50.8% underwent radical surgery, 85 PTS were dead at the time of analysis. 75 PTS (58.6%) were UM, 26 PTS (20,3%) were LM and 27 PTS (21,1%) were HM. On univariate analysis HM, LM and UM showed a PFS of 15.8, 10 and 9.1 ms, respectively (p = 0.1). OS was 38.7, 21 and 18.8ms (p= 0.06). On multivariate analysis UM and LM PTS had a statistically lower PFS vs HM PTS (HR = 2.57; p = 0.001; HR= 2.5; p = 0.007, respectively) and statistically lower OS (HR = 3.47; p 


MGMT promoter methylation status determined by pyrosequencing analysis may correlate to PFS and OS. We found a cut-off of 25% of methylation which determined two sub-groups of PTS having different clinical outcome; in particular, HM PTS had a significant longer PFS and OS.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings